Drugs / BCD-250
last change Apr 2022 re-read 3 minutes ago

BCD-250

Developed for
COVID-19
Investigated by
Biocad

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05037188 Aug 2021 → Apr 2022 COVID-19 Biocad Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BCD-250 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05037188 ↗